JPRN-UMIN000031269已完成未知
A multicenter phase II study of Tac + mini MTX as GVHD prophylaxis in patients undergoing cord blood transplantation - NJHSG-CBT18
orth Japan Hematology Study Group (NJHSG)0 个研究点目标入组 33 人开始时间: 2018年4月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients who are positive for HIV antibody. 2. Patients with active other malignancies. 3. Patients with active infectious disease. 4. Women who are pregnant, of childbearing potential, or lactating. 5. Patients who has a prior history of allogeneic transplantation. 6.Patients who experienced serious hypersensitivity or anaphylaxis to MTX and who have large amount of pleural effusion or ascites. 7.Patients who are not eligible for this study at the discretion of the investigator.
研究者
相似试验
已完成
3 期
A Phase III, randomized, double-blind study of TMC278 75 mg q.d. versus efavirenz 600 mg q.d. in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve HIV-1 infected subjects.HIV-1 infection - AIDS10021460NL-OMON32184Janssen-Cilag12
进行中（未招募）
1 期
A Phase III Clinical Trial Comparing Docetaxol and Cyclophosphamide (known as the TC chemotherapy regimen) to Doxorubicin, Cyclophosphamide and Docetaxol (known as the TAC chemotherapy regimen) for Women with Node-Positive orHigh-Risk Node-Negative, HER2-Negative Breast CancerAdjuvant Breast Cancer: Node positive or high risk node negative and HER 2 negativeMedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021587-15-IEICORG140
招募中
2 期
This is a phase 2, randomized, double blind, multicenter study evaluating the efficacy and safety of the combination of methotrexate plus UVB TL01 in vitiligo.2024-512766-34-00Centre Hospitalier Universitaire De Bordeaux48
进行中（未招募）
不适用
A Pilot Phase II combination study of Taxotere (Docetaxel) and Erbitux (Cetuximab) as a NEOadjuvant therapy in patients with triple-negative” (HR and Her2 negative) operable breast cancer. TENEO Study - TENEO studyCancer du sein opérable RH- et Her2-, en situation néoadjuvanteMedDRA version: 9.1Level: LLTClassification code 10022882Term: Invasive ductal breast cancerEUCTR2007-002371-13-FRCentre Jean Perrin
已完成
不适用
A phase II study for the safety and efficacy of TAS-102 and Bevacizumab for patients with unresectable colorectal cancer considering Oxaliplatin to stop and go.unresectable colorectal cancerJPRN-UMIN000022535Gunma University45